Breaking News

Theradaptive Awarded DOD Clinical Trial Award of up to $7.4M

Award will help Theradaptive scale up the production of its OsteoAdapt regenerative therapeutic product for spine and trauma repair.

Theradaptive, a biopharmaceutical company using protein engineering to create targeted therapeutics, has been awarded a U.S. Department of Defense (DOD) Clinical Trial Award of up to $7.4M with options, subject to FDA approval to begin phase I/II clinical studies. Awarded through the DOD’s Peer Reviewed Medical Research Program (PRMRP), the award recognizes the scientific merit of Theradaptive’s work in targeted regenerative therapeutics to create safer and more efficacious treatm...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters